Gennex Laboratories Ltd (GENNEX) — shareholding pattern, promoter holding, financials and share price
About Gennex Laboratories Ltd (GENNEX)
Gennex Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GENNEX and on the BSE under scrip code 531739. Its ISIN is INE509C01026.
Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries [1]
Gennex Laboratories Limited specializes in manufacturing and exports active pharmaceutical ingredients (APIs) and intermediates, focusing on expectorants, muscle relaxants, analgesics, and antifungal products.
The company maintains a global footprint with exports to countries including Germany, UK, Spain, Singapore, Canada, and more, marking its prominence in international markets.
Listed peers in Pharmaceuticals: Lyka Labs Ltd, Aarey Drugs & Pharmaceuticals Ltd, Ambalal Sarabhai Enterprises Ltd, Nectar Lifescience Ltd, Kerala Ayurveda Ltd, Coral Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹9.93 a share on 10 Jul 2026, Gennex Laboratories Ltd (GENNEX) was valued at a price-to-earnings ratio of 11.5x against an industry P/E of 36.41x. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 11.5x
- Industry P/E
- 36.41x
- EPS (TTM)
- ₹0.86
- Book value / share
- ₹7,68,423.77
- Debt / equity
- 0.05x
- Dividend yield
- 0%
- EBITDA margin
- 17.41%
- 52-week range
- ₹7.05 – ₹17.25
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Gennex Laboratories Ltd (GENNEX) reported revenue of ₹173 crore, net profit of ₹21 crore and earnings per share of ₹0.76. That compares with revenue of ₹138 crore and net profit of ₹18 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹60.96 crore and net profit ₹4.46 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 61 | 66 | 87 | 138 | 173 |
| Net profit (₹ cr) | 4 | 5 | 13 | 18 | 21 |
| EPS (₹) | 0.21 | 0.28 | 0.58 | 0.8 | 0.76 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 11.23% | 11.88% | 17.22% | 59.04% |
| Profit growth | 22.04% | 49.87% | 52.95% | 37.48% |
| Stock price CAGR | 4% | -2% | 11% | -33% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 23.63% of Gennex Laboratories Ltd (GENNEX) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0%. Promoters have pledged 21.8% of their holding. Market capitalisation was ₹241 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: JMS MINES & MINERALS PRIVATE LIMITED 3.25%, HUF 2.81%, ANUPRIYA CONSULTANTS PVT LTD 1.84%, Firm 1.71%, DORITE TRACON PRIVATE LIMITED 1.56%, SANJAY KUMAR 1.53%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 23.63% | 21.8% | - | 0% | 76.37% |
| Mar 2026 | 23.63% | 17.4% | - | 0% | 76.37% |
| Dec 2025 | 23.62% | 17.4% | - | 0% | 76.38% |
| Sep 2025 | 23.62% | 17.4% | - | 0% | 76.38% |
| Jun 2025 | 19.83% | 21.8% | - | 0% | 80.17% |
| Mar 2025 | 18.42% | 23.9% | - | 0% | 81.58% |
| Dec 2024 | 18.42% | - | - | 0% | 81.58% |
| Sep 2024 | 18.42% | - | - | 0% | 81.58% |